FOXA1 Alterations in Prostate Cancer: Expression, Mutation Classes, and Copy Number Changes

Discussion

Our analysis of TCGA PRAD highlights FOXA1 as a pivotal transcriptional regulator in prostate cancer, with alterations spanning expression, mutation, and copy number variation. FOXA1 mutations were classified into Class 1 (missense and in-frame indels in the Wing 2 region of the forkhead DNA-binding domain) and Class 2 (C-terminal truncations, including nonsense and frameshift events), following the framework described by Eyunni et al. (1). Copy number segmentation showed occasional gains or deletions but was not the principal determinant of FOXA1 oncogenic function, underscoring the primacy of mutation-driven transcriptional reprogramming.

Mechanistic distinctions between FOXA1 mutation classes. Class 1 mutations increase FOXA1’s nuclear mobility and alter DNA-binding specificity, pioneering noncanonical AR half-sites and recruiting NSD2 to deposit H3K36me2. This epigenetic remodeling stabilizes tumor-specific enhancer landscapes, driving AR-dependent adenocarcinoma, especially in the context of TP53 loss. In contrast, Class 2 truncations relieve C-terminal autoinhibition, enabling FOXA1 to activate KLF5- and AP-1-dominated enhancer programs. These alterations foster luminal-to-stemlike reprogramming, conferring plasticity and survival under androgen deprivation. Together, these mechanistic differences explain why Class 1 mutations act as initiators of tumorigenesis, while Class 2 truncations fuel therapy resistance.

Complementarity with PROX1. Our findings parallel those of PROX1, a transcription factor induced in ERG-positive tumors through TMPRSS2-ERG fusion-driven transcriptional reprogramming (4). PROX1 represents an ERG-dependent, epigenetically regulated axis of plasticity, while FOXA1 mutations function as structural gain-of-function events present across both ERG-positive and ERG-negative contexts. The complementarity lies in timing and mechanism: PROX1 induction appears to act as an early, fusion-linked mediator of plasticity, whereas FOXA1 mutations provide a durable structural mechanism to reshape enhancer usage. Both ultimately converge on lineage plasticity and therapy resistance.

Integration of Xena visualization and cBioPortal analysis. The complementary use of UCSC Xena and cBioPortal provided both visual and statistical validation of our findings. UCSC Xena enabled detailed visualization of FOXA1 expression patterns, mutation classes, and copy number changes (Figure 1), illustrating the broad expression of FOXA1 across tumors and the distinct clustering of Class 1 and Class 2 variants. In parallel, cBioPortal offered quantitative mutual exclusivity analysis (Table I), demonstrating that FOXA1 alterations are significantly mutually exclusive with both TMPRSS2 and ERG (q <0.001). Together, these analyses confirm – both visually and statistically – that FOXA1 and ERG act as alternative, nonredundant transcriptional drivers in prostate cancer.

The FGA analysis (Figure 2) provides further insight into the genomic context of FOXA1 alterations. The lack of a significant Pearson correlation indicates that FOXA1 mutations are not tightly coupled to genome-wide copy number changes, reinforcing the conclusion that FOXA1 primarily drives cancer through transcriptional reprogramming rather than chromosomal instability. Nonetheless, the significant Spearman correlation implies that FOXA1 mutations may be enriched in tumors with a generally more unstable genome, raising the possibility that genomic stress could facilitate or select for FOXA1-driven pathways. This pattern contrasts with ERG fusions, which are highly specific structural rearrangements, and aligns with PROX1, which is epigenetically induced rather than linked to global copy number burden. Together, these data emphasize that FOXA1 functions as a focused, transcription factor-driven driver of prostate cancer, rather than a byproduct of widespread genomic instability.

Therapeutic implications and hurdles. Targeting FOXA1-driven tumors remains challenging, as FOXA1 lacks enzymatic activity. Indirect approaches focus on cooperating chromatin regulators. Nuclear Receptor Binding SET Domain Protein 2 (NSD2) inhibitors, relevant to Class 1 FOXA1 tumors, are under development but remain limited by poor potency and selectivity within the SET domain family. The SET domain is a protein domain that typically has methyltransferase activity. KTX-1001, a first-in-class NSD2 inhibitor, has recently entered clinical trials for multiple myeloma, demonstrating translational feasibility but highlighting the gap in prostate-specific development (6). Bromodomain and extra-terminal (BET) inhibitors and activator protein-1 (AP-1) antagonists could disrupt enhancer circuitry driven by Class 2 FOXA1 truncations, yet pan-BET inhibitors often cause dose-limiting toxicities such as thrombocytopenia and gastrointestinal complications (7). Histone deacetylase (HDAC) inhibitors, which suppress PROX1, show promise but raise concerns about broad systemic toxicity, particularly hematologic and cardiac effects (8). These challenges emphasize that while mechanistic vulnerabilities are compelling, the path to clinical translation requires more selective next-generation inhibitors and careful biomarker stratification.

Future directions. Future work should integrate FOXA1 and PROX1 status into molecular subtyping frameworks for prostate cancer. Stratifying patients by ERG fusion, FOXA1 mutation class, and PROX1 expression could clarify whether these factors act sequentially (ERG → PROX1 induction → FOXA1 plasticity) or in parallel as independent drivers. Large-scale datasets such as TCGA PRAD, SU2C-CRPC, and CPGEA provide the foundation for such analyses.

A parallel priority is the development of higher-quality chemical probes. For NSD2, more selective inhibitors are needed to overcome challenges of SET domain homology. BET inhibitors must be refined for tolerability, and epigenetic strategies to suppress PROX1 require more precise targeting to minimize toxicity. Incorporating FOXA1 and PROX1 biomarkers into early-phase clinical trials of chromatin-directed therapies will be critical to determine whether transcription factor-driven plasticity can be therapeutically constrained.

Finally, patient-derived models – xenografts, organoids, and spatial transcriptomics – should be prioritized to capture intratumoral heterogeneity and therapy resistance. These platforms will be essential to validate mechanistic hypotheses and guide biomarker-driven trials.

Study limitations. The most important limitation is reliance on retrospective, correlative data. The findings are associations and not direct proof of causation. The results heavily depend on the framework established by Eyunni et al. (1) to interpret the biological meaning of the mutation classes, meaning the core mechanistic hypotheses are borrowed and not directly tested in this analysis.

Another major weakness is the generalizability of the findings. The TCGA cohort is primarily composed of treatment-naïve tumors, which may not accurately reflect the genomic landscape of advanced, castration-resistant prostate cancer. The study’s conclusions about FOXA1’s role in therapy resistance are therefore based on an assumption that these mutations are present or gain importance in later stages, which this dataset cannot directly prove.

The use of bulk RNA-seq data also limits the resolution of the analysis. Bulk sequencing averages gene expression and mutation profiles across an entire tumor sample. This can obscure intratumoral heterogeneity, where distinct cell populations with different genetic alterations may coexist. Single-cell sequencing would be necessary to truly understand the complex interactions and lineage plasticity discussed in the article’s conclusion.

Finally, while cBioPortal adds statistical rigor to the exclusivity analysis, these associations remain correlative and require functional validation in experimental system.